Investor News

August 8, 2008 - Interim results for the six months to 30 June 2008

Cyprotex PLC 

(“Cyprotex“ or “the Company“ or “the Group“ )

Cyprotex PLC (LSE: CRX), the drug discovery, technology and information company, today reports its Interim results for the half year ended 30 June 2008.

Financial Highlights

Revenues for the period ended June 2008 expanded significantly on the comparable period, up 33% to 2.25 million GBP (1H 2007: 1.69 million GBP).
The Group recorded a net profit for the first time at 56,000 GBP (1H 2007: loss 418,000 GBP).
Cash and cash equivalents ended the period largely unchanged from the 2007 year end position, at 276,000 GBP (2007: 301,000 GBP), although the second half of the year will bear the weight of certain non-recurring costs associated with the departure of Cyprotex's previous Chief Executive Officer, Mr Robert Morrisson Atwater.
At a General Meeting on 14th July 2008, shareholders authorised the placement of 40 million new ordinary shares at 2.5p each to both new and existing shareholders raising 1 million GBP (gross). The closing date for subscriptions associated with this placement was 26th August 2008, following which the fund raising was declared successfully completed.
Commenting on the results, Nikolas Sofronis, Chairman of Cyprotex PLC, said:

“A number of important steps took place during the first half of 2008. As a result, Cyprotex now possesses greater confidence and remains optimistic of securing further growth in the second half.”

Download Cyprotex Interim Results for the six months to 30 June 2008

For further information:

Cyprotex PLC
Dr Anthony Baxter, CEO
Tel: +44 (0)1625 505 100
ir@cyprotex.com
www.cyprotex.com

Russell Gibbs, CFO
Tel: +44 (0)1625 505 100
ir@cyprotex.com
www.cyprotex.com

Nomura Code Securities Limited
Charles Walker, Giles Balleny
Tel: +44 (0)20 7776 1200
cew@nomuracode.com
www.nomuracode.com

Media Enquires
Pelham PR
Simon Miller
Tel: +44 (0)20 3178 4419
simon.miller@pelhampr.com